Celularity Inc

CELUNASDAQ · USD
0.63USD0.00 (-7.99%)
232

Celularity Inc (CELU) Covered Calls

Celularity Inc trades in the Biotechnology industry with an IV Rank of 0.40%, low versus the past year. CELU's highest covered call setup is the $2.50 strike expiring May 21, 2027, sorted by theoretical annualized return. It's 267.65% out of the money with 190 days to expiration, a 275.00% return until expiration, and a 528.29% theoretical annualized return. Across the setups shown, annualized returns run from 200.61% to 528.29% at strikes between $1.00 and $2.50, with 99 to 190 days to expiration, as of Nov 12, 2026.

Read more

Running CELU covered calls helps you generate income from Celularity Inc shares you already own, turning a long stock position into a yield producing asset. A covered call means holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike. Use our scanner to find the best CELU covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.

A covered call pairs limited risk with a clear income profile. If CELU stays below the strike at expiration, you keep the premium and the shares. If it rises above, you deliver the stock at the strike and still pocket the premium. Selling CELU covered calls works best when implied volatility is elevated, since richer premiums improve the risk reward. Key inputs include strike selection relative to delta, days to expiration, annualized return, and probability of assignment, all of which determine whether a given CELU covered call is worth writing.

Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, a placental-derived CAR-T therapy, which is in Phase I clinical trial for the treatment of B-cell malignancies; CYNK-001, placental-derived unmodified natural killer (NK) cell that is in Phase I clinical trial to treat acute myeloid leukemia, as well as in Phase I/IIa clinical trial for the treatment of glioblastoma multiforme and COVID-19; CYNK-101, an allogeneic genetically modified NK cell, which is in Phase I clinical trial to treat HER2+ gastric and gastroesophageal cancers; APPL-001, a placenta-derived mesenchymal-like adherent stromal cell that is in a pre-clinical stage for the treatment of Crohn's disease; and PDA-002, a placenta-derived mesenchymal-like adherent stromal cell, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy.

2027-05-211902.50267.650.050.95187.00275.00528.29-7.35+0.8400.90
2027-05-211901.50120.590.101.0592.00135.29259.91-14.71+0.9210.95
2027-02-19991.0047.060.051.0037.0054.41200.61-7.35+0.8800.95

As of Nov 12, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →

Stock Statistics

  • IndustryBiotechnology
  • SectorHealthcare
  • IV Rank0.40% Low
  • Market cap (M$)20
  • 52 weeks high-75.29%
  • 52 weeks low12.50%
  • Analyst recommendationBuy
    2.00
  • Target price$6.00
    852.38% above the current stock price
  • Dividend—
  • Payout ratio—
  • Earnings date2026-10-20
  • P/E—
  • Future P/E—
  • EPS (ttm)-1.68
  • EPS growth next 5 years—

As of Nov 13, 2026